PW Medtech acquires Chinese medical device peer; FDA approves brain function analysis system;

@FierceMedDev: ICYMI yesterday: Home healthcare design considerations addressed in FDA final guidance. Story | Follow @FierceMedDev

@StacyALawrence: Philips, Accenture create brain wave app for immobilized patients. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. Story | Follow @MichaelGFierce

@EmilyWFierce: Quick point-of-care devices could be the next "holy grail" in detecting infectious diseases like Ebola. More from NBC News | Follow @EmilyWFierce

> Chinese medical device company PW Medtech Group acquired Beijing Lima Tianxinfu Medical Devices for 802.6 million RMB ($130.1 million). Release

> The FDA gave its approval for ElMindA's non-invasive brain function BNA Analysis System. Release

> SynCardia Systems' Total Artificial Heart received FDA approval, giving the company the go-ahead on both their unique heart valves and segmented polyurethane solution. Release

> Oxford Immunotec acquired rheumatology and infectious disease-concentrated company Boulder Diagnostics for $7.9 million. Release

Biotech News

@FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. Article | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> Regeneron hits the gas on R&D, pouring cash into a blockbuster pipeline. More

> Auris pulls off a $56M IPO to bankroll its ear treatments. Report

> Sarepta leaps into Ebola spotlight with a shelved therapy. Story

> Cytori shares slammed as safety concerns halt stem cell trials. Article

Pharma News

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Story | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Novartis hangs 'For Sale' sign on U.S. plant as it prepares to close and sell facility and lay off 500. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers. Report | Follow @CarlyHFierce

> AbbVie decides against Supreme Court appeal for ruling that extended rights to gays. More

> Zogenix seeks partner, steers Zohydro marketing away from weak New England. Story

> UCB hops on pharma's spinoff wagon with potential $2B sale of generics business. Article

Drug Delivery News

> BD launches AutoShield Duo pen for diabetics. Report

> BioDelivery Sciences International to add 80 patients to clinical trial of Clonidine Topical Gel. Item

> Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. Article

> Biodegradable film strip enabling 14 months of drug delivery prototyped by MIT team. Story

> Stentys ditches bare metal stents as customers move to drug-eluting versions. Article

Diagnostics News

> Johns Hopkins group scrutinizes possible biomarker for suicide risk. News

> Dx industry is cautious, wary and diplomatic in the face of FDA's push to regulate LDTs. Report

> MGC Diagnostics completes Belgian M&A deal with an eye on globalization. More

> Exosome Diagnostics replaces CEO and relocates as it preps for commercialization. Article

> OncoCyte rolls out massive trial for bladder cancer Dx. Story

Pharma Marketing News

> Third to market may still be a charm for Lilly, BI's new diabetes med Jardiance. More

> GSK relaunches COPD patient site with blockbuster sales on the line. Item

> The formularies are here! Brace yourselves for the 48 new exclusions. Report

> J&J Baby aims to turn ingredients scandal into sales with 'transparent' ad campaign. Story

> Teva eyes 'hard switch' to hit Copaxone goals if the soft sell isn't enough. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.